Lilly To Discontinue Two Humulins - Ultralente and Lente - By Year-End
This article was originally published in The Pink Sheet Daily
Company says declining commercial demand is the reason for its decision to discontinue production of the longer-acting Humulins as well as Iletin insulins. Lilly sends out "Dear Doctor" letters and will help transition patients to the company's other insulin products through coupons for free samples.
You may also be interested in...
Lilly will discontinue only the Ultralente and Lente formulations of Humulin human insulin. The firm will continue to manufacture Humulin R, N, 70/30 and 50/50 formulations. "The Pink Sheet" DAILY had inadvertently suggested that all Humulin formulations were to be discontinued by year-end (1"The Pink Sheet" DAILY, July 6, 2005)
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.